# To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas

> **NCT03277209** · PHASE1 · TERMINATED · sponsor: **Weill Medical College of Cornell University** · enrollment: 2 (actual)

## Conditions studied

- Pancreas Cancer

## Interventions

- **DRUG:** Plerixafor

## Key facts

- **NCT ID:** NCT03277209
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-25
- **Primary completion:** 2019-12-30
- **Final completion:** 2019-12-30
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** terminated due to slow accrual
- **Last updated:** 2020-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03277209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03277209, "To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03277209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*